Physician profile
Liren Li
NPI 1194832683
$2,234.14
in general payments reported to CMS, 2019-2025
18 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $131 · 2021: $189 · 2022: $406 · 2023: $424 · 2024: $473 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $340.27 | 2021-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $335.81 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $318.04 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $273.48 | 2019-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $133.22 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.29 | 2022 | |
| Janssen Pharmaceuticals, INC | $119.65 | 2023-2025 | Spravato |
| Collegium Pharmaceutical, INC. | $119.44 | 2025 | Jornay Pm |
| Intra-Sana Laboratories | $111.11 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Alexion Pharmaceuticals, INC. | $96.34 | 2025 | Ultomiris |
| Corium, LLC | $83.28 | 2022-2023 | Azstarys |
| Lundbeck LLC | $65.35 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $30.81 | 2023-2024 | Sunosi, Auvelity |
| Idorsia Pharmaceuticals US INC | $29.30 | 2023 | Quviviq |
| Tris Pharma INC | $18.81 | 2025 | Onyda Xr |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $13.77 | 2019 | |
| Neurocrine Biosciences, INC. | $13.32 | 2021 | |
| Alkermes, INC. | $11.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liren Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.